Mark Baker

Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

Wesley C. Van Voorhis, John H. Adams, Roberto Adelfio et al. · PLoS Pathogens · 2016 · 441 citations · Full text

Drug Target, Bioorganic Chemistry, Antiparasitic Agent +17

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno et al. · AIDS · 2021 · 189 citations · Full text

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

Aung Pyae Phyo, Podjanee Jittamala, François Nosten et al. · The Lancet Infectious Diseases · 2015 · 187 citations · Full text

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos‐Cuentas, Martín Casapía, Raúl Chuquiyauri et al. · The Lancet Infectious Diseases · 2018 · 139 citations · Full text

A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

James McCarthy, Thomas Rückle, Elhadj Djeriou et al. · Malaria Journal · 2016 · 125 citations · Full text